Mesoblast Net Income vs. Price To Book

MESO Stock  USD 15.85  1.07  6.32%   
Based on Mesoblast's profitability indicators, Mesoblast may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in March. Profitability indicators assess Mesoblast's ability to earn profits and add value for shareholders.
 
Net Loss  
First Reported
2012-09-30
Previous Quarter
-27.1 M
Current Value
-27.1 M
Quarterly Volatility
12.9 M
 
Yuan Drop
 
Covid
 
Interest Hikes
As of the 28th of February 2026, Price To Sales Ratio is likely to drop to 79.18. In addition to that, Days Sales Outstanding is likely to drop to 344.69. At this time, Mesoblast's Accumulated Other Comprehensive Income is very stable compared to the past year. As of the 28th of February 2026, Income Tax Expense is likely to grow to about 311.9 K, while Operating Income is likely to drop (59 M). At this time, Mesoblast's Gross Profit is very stable compared to the past year. As of the 28th of February 2026, Gross Profit Margin is likely to grow to 0.85, while Pretax Profit Margin is likely to drop (5.59).
For Mesoblast profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Mesoblast to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Mesoblast utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Mesoblast's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Mesoblast over time as well as its relative position and ranking within its peers.
Check out Correlation Analysis.
To learn how to invest in Mesoblast Stock, please use our How to Invest in Mesoblast guide.By analyzing Mesoblast's earnings estimates, investors can diagnose different trends across Mesoblast's analyst sentiment over time as well as compare current EPS estimates against different timeframes. Please be aware that the consensus of earnings estimates for Mesoblast is based on EPS before non-recurring items and includes expenses related to employee stock options.
 
Yuan Drop
 
Covid
 
Interest Hikes
Mesoblast is projected to generate -0.36 in earnings per share on the 30th of June 2024. Mesoblast earnings estimates show analyst consensus about projected Mesoblast EPS (Earning Per Share). It derives the highest and the lowest estimates based on Mesoblast's historical volatility. Many public companies, such as Mesoblast, manage the perception of their earnings on a regular basis to make sure that analyst estimates are accurate. Future earnings calculations are also an essential input when attempting to value a firm. By analyzing Mesoblast's earnings estimates, investors can diagnose different trends across Mesoblast's analyst sentiment over time as well as compare current estimates against different timeframes.
Will Biotechnology sector continue expanding? Could Mesoblast diversify its offerings? Factors like these will boost the valuation of Mesoblast. Expected growth trajectory for Mesoblast significantly influences the price investors are willing to assign. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Mesoblast data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share
(0.85)
Revenue Per Share
0.14
Quarterly Revenue Growth
4.586
Return On Assets
(0.05)
Return On Equity
(0.19)
Investors evaluate Mesoblast using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Mesoblast's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Mesoblast's market price to deviate significantly from intrinsic value.
Understanding that Mesoblast's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Mesoblast represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Conversely, Mesoblast's market price signifies the transaction level at which participants voluntarily complete trades.

Mesoblast Price To Book vs. Net Income Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Mesoblast's current stock value. Our valuation model uses many indicators to compare Mesoblast value to that of its competitors to determine the firm's financial worth.
Mesoblast is regarded second in net income category among its peers. It is rated below average in price to book category among its peers . Mesoblast reported last year Net Loss of (91.93 Million). The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Mesoblast's earnings, one of the primary drivers of an investment's value.

Mesoblast Price To Book vs. Net Income

Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.

Mesoblast

Net Income

 = 

(Rev + Gain)

-

(Exp + Loss)

 = 
(102.14 M)
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.

Mesoblast

P/B

 = 

MV Per Share

BV Per Share

 = 
3.65 X
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.

Mesoblast Price To Book Comparison

Mesoblast is currently under evaluation in price to book category among its peers.

Mesoblast Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Mesoblast, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Mesoblast will eventually generate negative long term returns. The profitability progress is the general direction of Mesoblast's change in net profit over the period of time. It can combine multiple indicators of Mesoblast, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income114.4 M120.1 M
Operating Income-56.2 M-59 M
Income Before Tax-91.6 M-87 M
Total Other Income Expense Net-35.4 M-33.7 M
Net Loss-91.9 M-87.3 M
Income Tax Expense297 K311.9 K
Net Loss-91.9 M-96.5 M
Net Loss-73.7 M-77.4 M
Net Interest Income-17.1 M-18 M
Interest Income4.1 M4.3 M
Change To Netincome19.5 M20.5 M
Net Loss(0.10)(0.11)
Income Quality 0.44  0.42 
Net Income Per E B T 0.90  0.73 

Mesoblast Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Mesoblast. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Mesoblast position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Mesoblast's important profitability drivers and their relationship over time.

Mesoblast Earnings per Share Projection vs Actual

Use Mesoblast in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Mesoblast position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Mesoblast will appreciate offsetting losses from the drop in the long position's value.

Mesoblast Pair Trading

Mesoblast Pair Trading Analysis

The ability to find closely correlated positions to Mesoblast could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Mesoblast when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Mesoblast - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Mesoblast to buy it.
The correlation of Mesoblast is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Mesoblast moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Mesoblast moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Mesoblast can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Mesoblast position

In addition to having Mesoblast in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run USA Crypto Assets Thematic Idea Now

USA Crypto Assets
USA Crypto Assets Theme
An experimental p2p digital currency that is accepted by many vendors in null. The USA Crypto Assets theme has 0 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize USA Crypto Assets Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Mesoblast offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Mesoblast's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Mesoblast Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Mesoblast Stock:
Check out Correlation Analysis.
To learn how to invest in Mesoblast Stock, please use our How to Invest in Mesoblast guide.
You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
To fully project Mesoblast's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Mesoblast at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Mesoblast's income statement, its balance sheet, and the statement of cash flows.
Potential Mesoblast investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Mesoblast investors may work on each financial statement separately, they are all related. The changes in Mesoblast's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Mesoblast's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.